Business Context and Reporting Period
Company: Bioanalytical Systems, Inc. (Note: Metadata lists "Inotiv, Inc." but the filing text identifies the registrant as Bioanalytical Systems, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 1997
Business Description: Manufactures scientific instruments for trace organic compound determination and provides laboratory services, consulting, and research. The company recently acquired Vetronics, Inc. to expand its physiology instrumentation portfolio.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 1997 | Three Months Ended Dec 31, 1996 |
|---|---|---|
| Total Revenue | $4,330 | $3,516 |
| Gross Profit | $2,483 | $2,179 |
| Operating Income | $324 | $347 |
| Net Income | $196 | $188 |
| Diluted EPS | $0.05 | $0.05 |
| Cash & Equivalents (End of Period) | $3,667 | $309 |
| Net Cash from Operating Activities | $461 | $285 |
| Long-Term Debt (Excl. Current) | $286 | $5,045 |
Liquidity: The company holds $3.7 million in cash and cash equivalents. It has two lines of credit totaling up to $3.2 million in availability, neither of which was utilized as of December 31, 1997.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 23.2% to $4.3 million, driven by a 48% increase in services revenue ($1.7M vs $1.1M) and a 11% increase in product revenue ($2.6M vs $2.4M) due to the Vetronics acquisition.
- Operating Expenses: General and administrative expenses rose 57.7% to $612,000, attributed to increased property taxes from new facilities and costs related to the acquisition and IPO. R&D expenses increased 30.8% to $476,000.
- Debt Reduction: Long-term debt decreased significantly from $5.0 million to $286,000. A $5.0 million credit facility was fully repaid using IPO proceeds.
- Cash Position: Cash and cash equivalents surged from $161,000 (Sept 30, 1997) to $3.7 million (Dec 31, 1997) following the Initial Public Offering (IPO).
Guidance, Outlook, and Risks
Capital Resources: Management believes cash from operations, existing credit lines, and remaining IPO proceeds ($3.1 million invested in money market funds) are sufficient to fund working capital and capital expenditure requirements.
Future Expenditures: The company anticipates increased capital expenditures in fiscal 1998 and 1999 for facility renovations, construction, and laboratory equipment. No firm commitments exist beyond current facility expansion.
Risks and Contingencies:
- Forward-Looking Statements: The filing contains forward-looking statements regarding strategic plans and profitability which are subject to risks and uncertainties.
- Debt Covenants: The company is negotiating to increase credit line amounts and extend expiration dates (currently March 1, 1998), with no assurance of success.
- Acquisition Integration: The acquisition of Vetronics includes a contingent purchase price based on future profitability, introducing uncertainty in final valuation.
Investor Verification Checklist
- IPO Proceeds Usage: Verify the allocation of the $9.4 million net IPO proceeds, specifically the $6.3 million used to repay indebtedness.
- Vetronics Acquisition: Confirm the performance of the acquired Vetronics unit against the contingent payment criteria for the next two years.
- Debt Renewal: Monitor the status of negotiations to extend the $2.2 million and $1.0 million lines of credit expiring March 1, 1998.
- Capital Expenditures: Track actual spending against the anticipated increase in facility construction and equipment purchases for fiscal 1998.
- Margin Trends: Monitor the cost of revenue for products, which rose to 35.9% of product revenue, to ensure it does not erode gross margins further.